BondGR, GarroAC, GilbertDL: Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clin Toxicol (Phila), 45: 182–185, 2007.
2.
ChengJY, ChenRY, KoJS, NgEM: Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl), 194:197–209, 2007.
3.
DumanI, BaklaciK, TanAK, KalyonTA: Unusual case of camptocormia triggered by lumbar-disc herniation. Clin Rheumatol, 27:525–527, 2008.
4.
FinstererJ, StroblW: Causes of camptocormia. Disabil Rehabil, 33:1702–1703, 2011.
5.
FinstererJ, StroblW: Presentation, etiology, diagnosis, and management of camptocormia. Eur Neurol, 64:1–8, 2010.
6.
KobayashiT, WashiyamaK, IkedaK: Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine. Neuropsychopharmacol, 35:1560–1569, 2010.
7.
LedbetterM: Atomoxetine use associated with onset of a motor tic. J Child Adolesc Psychopharmacol, 15:331–333, 2005.
8.
NaranjoCA, BustoU, SellersEM, SandorP, RuizI, RobertsEA, JanecekE, DomecqC, GreenblattDJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 30:239–245, 1981.
9.
PárragaHC, PárragaMI, HarrisDK: Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder. Int J Psychiatry Med, 37:415–424, 2007.
10.
RajmohanV, ThomasB, SreekumarK: Case study: Camptocormia, a rare conversion disorder. J Am Acad Child Adolesc Psychiatry, 43:1168–1170, 2004.
11.
SearsJ, PatelNC: Development of tics in a thirteen-year-old male following atomoxetine use. CNS Spectr, 13:301–303, 2008.
12.
ShuperA, KellerA, ArbelN, InbarD, SteinbergT: Trauma-induced dystonia and camptocormia in a child. Pediatr Neurol, 36:184–185, 2007.
